Several reasons may explain this discrepancy: i) differences in the deepening of clinical investigations, ii) types of FBXW7 molecular defect in the patients, their individual genetic background and variable penetrance of the mutations, and iii) use or combination of different chemotherapeutic treatments based on anti-cancer drugs, or immunosuppressants and inhibitors of mTOR, that is a target of FBXW77. Here, MTOR is linked to cancer.